エリスロポエチン製剤市場レポート：2031年までの動向、予測、競合分析

世界のエリスロポエチン製剤市場の将来は、がん、腎疾患、神経疾患市場に機会があり、有望視されています。世界のエリスロポエチン製剤市場は、2025年から2031年までのCAGRが1.8%で、2031年までに推定73億米ドルに達すると予想されています。この市場の主な促進要因は、慢性疾患の症例が日々増加していることと、CKDの症例数が増加していることです。

• Lucintel社の予測では、タイプ別では生物学的製剤が予測期間中も大きなセグメントであり続けると思われます。
• 用途別では、腎疾患が引き続き最大セグメントです。
• 地域別では、北米が予測期間中最大の地域であり続けると思われます。

エリスロポエチン製剤市場の戦略的成長機会

戦略的には、エリスロポエチン製剤市場にはいくつかの用途で成長を達成できる要因があります。これらの機会は現在の治療選択肢を改善し、患者の予後改善につながる可能性を秘めています。これらの機会には以下のようなものがあります。：

• バイオシミラー医薬品の拡大：バイオシミラーの開発と商業化は、低コストの治療に対する需要の高まりにより、企業にとって新たな事業開発の機会となります。このような拡大は、患者へのアクセシビリティを拡大し、貧血の有病率が高い地域での成長を促す可能性があります。
• 併用療法の開発：貧血治療のためにEPOを他の治療法と併用することは、成長の機会となります。併用療法が患者管理に及ぼす影響を調査する臨床試験は、組織にとって実り多い事業となり得ます。
• 小児への応用に関する調査：小児集団における効率的な貧血治療に対する需要は高まっています。適切なEPO製剤を開発し、小児における安全性と有効性を試験するという実践が続けば、新たな市場が創出され、若年患者の健康状態が改善されるでしょう。
• 患者教育プログラムの重視患者教育プログラムを実施することは、貧血とEPO療法の利点についての理解を促進するのに役立ちます。患者に知識を与えることで、ヘルスケアプロバイダーによる診断率や治療コンプライアンスを向上させることができます。
• デジタルヘルスプラットフォームの活用：テレヘルスやモバイルヘルスアプリケーションなどの医療行為を取り入れることで、患者の管理とコントロールを向上させることができます。このようなプラットフォームは、特に遠隔地に住む人々にとって医療サービスへのアクセシビリティを向上させるため、市場を後押しします。

エリスロポエチン製剤市場におけるこうした戦略的成長機会は、革新的思考を刺激しながら患者ケアを改善し、治療の選択肢を広げる可能性を秘めています。このような成長機会に注目することで、利害関係者は貧血に対する全身的な取り組みを推進し、より良い結果を得ることができると思われます。

エリスロポエチン製剤市場の促進要因・課題

エリスロポエチン製剤市場に存在する多くの促進要因・課題が、同市場の成長・開拓に影響を与える可能性があります。主な市場要因には、技術的、経済的、規制的なものがあり、これらはすべて市場に影響を与えます。以下に、この分野に存在する様々な促進要因と課題について説明します。

エリスロポエチン製剤市場を牽引する要因は以下の通り：

• 技術の進歩：バイオテクノロジーのさらなる開発は、天然のエリスロポエチンの新しい製剤や送達様式へと進展しています。こうした改良により治療が容易になり、市場機会が拡大します。
• 貧血の有病率の増加：慢性疾患、人口の高齢化、生活習慣によって引き起こされる貧血の発生率の増加が、エリスロポエチン治療薬に対する需要を増大させています。より多くの患者が効果的な治療を求めているため、このような有病率の上昇が市場成長の原動力となっています。
• バイオシミラー競合：エリスロポエチンの競合領域にはバイオシミラーが参入し、競争の激化とコスト削減が進んでいます。こうした動向は、特にコストが治療の重要な要素である国々において、患者の治療へのアクセスを向上させます。
• イノベーションに対する規制上の支援：新規治療薬やバイオシミラーに対する規制当局の姿勢は、承認プロセスをより効率的にするために変化しているようです。このような環境は、製薬企業による研究開発活動への資金提供を促し、進歩をもたらします。
• 啓発・教育活動：貧血とその治療に関する知識の増加は、ヘルスケアプロバイダーや患者が正しい診断を下し、より早く治療を開始することにも役立っています。市場の見通しは、マーケティング戦略や製品の革新性だけでなく、患者の教育レベルによっても決まります。

エリスロポエチン製剤市場の課題は以下の通り：

• 限られた患者意識：医療従事者を対象とした啓蒙活動にもかかわらず、多くの患者は貧血やEPO療法の有効性を知りません。この知識不足は診断の遅れや誤りにつながり、その結果、最適な管理が行われず、健康上の不利益をもたらす可能性があります。治療開始率を上げるためには、患者教育を改善する必要があります。
• バイオシミラーとの競合：バイオシミラーは治療の選択肢を増やし、治療費をより安価にする一方で、競合の激化というマイナス面もあります。この競合は価格競争につながり、ブランドEPO製剤の売上を圧迫する可能性があります。企業は、このような環境変化の中で競争力を維持するための革新的な方法を見つける必要があります。
• 安全性と有効性に関する懸念：患者の安全性と有効性に関する懸念は、特に特定の患者にとっては治療の障壁となりえます。EPO療法による高血圧や血栓症のリスク増加などの問題は、治療の決定に影響を及ぼす可能性があります。これらの懸念に対処するためには、継続的な研究と市販後調査が必要となります。

商業的には、これらの課題は、リーチ、コンプライアンス、患者の転帰を制限することにより、市場に影響を与えます。教育、規制の強化、継続的な技術開発を通じてこれらの課題を解決することは、EPO療法の有効性を向上させ、市場を拡大する上で極めて重要です。

目次

第1章 エグゼクティブサマリー

第2章 世界のエリスロポエチン製剤市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2019年から2031年までの市場動向と予測分析

• マクロ経済動向（2019～2024年）と予測（2025～2031年）
• 世界のエリスロポエチン製剤市場の動向（2019～2024年）と予測（2025～2031年）
• タイプ別：世界のエリスロポエチン製剤市場
  • 生物学的
  • バイオシミラー
• 製品別：エリスロポエチン製剤の世界市場
  • エリスロポエチン
  • ダルベポエチンアルファ
• 用途別：エリスロポエチン製剤の世界市場
  • がん
  • 腎臓病
  • 神経学
  • その他

第4章 2019年から2031年までの地域別市場動向と予測分析

• 地域別：エリスロポエチン製剤の世界市場
• 北米のエリスロポエチン製剤市場
• 欧州のエリスロポエチン製剤市場
• アジア太平洋地域のエリスロポエチン製剤市場
• その他地域のエリスロポエチン製剤市場

第5章 競合分析

• 製品ポートフォリオ分析
• 運用統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • タイプ別：世界のエリスロポエチン製剤市場の成長機会
  • 製品別：世界のエリスロポエチン製剤市場の成長機会
  • 用途別：世界のエリスロポエチン製剤市場の成長機会
  • 地域別：世界のエリスロポエチン製剤市場の成長機会
• 世界のエリスロポエチン製剤市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界のエリスロポエチン製剤市場の能力拡大
  • 世界のエリスロポエチン製剤市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Johnson & Johnson
• Novartis
• Teva Pharmaceutical Industries
• Amgen
• F. Hoffmann-La Roche
• LG Chem
• Biocon
• Intas Pharmaceuticals
• Sun Pharmaceutical Industries
• Dr. Reddy's Laboratories

The future of the global erythropoietin drug market looks promising with opportunities in the cancer, renal disease, and neurology markets. The global erythropoietin drug market is expected to reach an estimated $7.3 billion by 2031 with a CAGR of 1.8% from 2025 to 2031. The major drivers for this market are the growing day-by-day cases of chronic disease and a growing number of CKD cases.

• Lucintel forecasts that, within the type category, biologics will remain the larger segment over the forecast period.
• Within the application category, renal disease will remain the largest segment.
• In terms of regions, North America will remain the largest region over the forecast period.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Erythropoietin Drug Market

As new challenges arise in the erythropoietin drug market, several emerging trends are becoming apparent that are defining the market's geographical dimensions. These trends are the outcomes of the growth of technology, changing patient requirements, and policy alterations. The following are the reasons why some of the trends are pertinent to the market today:

• Emergence of Biosimilars: The establishment of biosimilars has revolutionized the EPO market, creating low-cost substitutes to the original marketed brands. This trend increases patients' access to much-needed therapies and creates competition between manufacturers, which in turn lowers prices and enhances availability.
• Move towards Personalized Medicine: There is increased attention to patients and more healthcare providers focusing on profile-based prescribing of EPO therapies. This trend increases the efficiency of treatment and decreases side effects, leading to better patient compliance and outcomes.
• Widened Use of EPO: There is a steady increase in research on erythropoietin for diseases outside its conventional use. More research is being done on how this drug can be used in treating various forms of anemia, heart failure, and inflammatory diseases, thereby increasing the patient base.
• Enhancement of the Drug Delivery System: Advancements in drug delivery systems, such as the use of sustained-release formulations and other EPO therapy systems, are improving the safety and efficacy of these therapies. With these improvements, fewer injections will be required, yielding better patient adherence and satisfaction with the overall treatment.
• Emphasis on the Importance of Anemia Awareness: To improve outcomes in most patients, raising awareness and educating patients and healthcare practitioners about the condition and the treatment of its cause are the factors leading to early disease diagnosis and treatment initiation. This trend is critical for enhancing patient outcomes and boosting the market.

These new emerging trends are reshaping the erythropoietin drug market by enhancing available treatment options, maximizing further patient participation, and encouraging creativity among the involved players. As the changes progress, these trends will lead to better handling of anemia and a higher quality of life for patients.

Recent Developments in the Erythropoietin Drug Market

Important changes in the erythropoietin drug markets emphasize efficacious therapeutic measures, research, and professional management, as well as accessibility in the market. These changes are vital in addressing concerns related to patient safety and, from a broader perspective, the management of anemia. Here are five critical changes taking place in the market:

• Approval of New Biosimilars: The presence of numerous new players introducing biosimilar EPO products has intensified competition and lowered prices in the markets. Such low-cost substitutes facilitate access to life-saving treatments for patients, thus increasing the erythropoietin market.
• Introduction of Extended-Release Formulations: Commercial variants of EPO formulations, now available in the extended-release form, have made it possible to reduce the number of times patients must take the injection. This new trend aims to solve treatment adherence issues, thus ensuring better patient health outcomes.
• Studies on EPO's New and Salvage Uses in Liberty and Actives: This research investigates new therapeutic applications of EPO, including its possible use in the treatment of inflammatory chronic anemia. These studies might increase the range of EPO applications, which would increase the marketability of the product.
• Collaborations: The time taken to develop innovative EPO therapies is being reduced due to cooperation between pharmaceutical firms and research organizations. Such cooperation is important to leverage technological developments in the provision of alternative treatment services.
• Improving Access: A "waitlist" for EPO products that neither works for Sumitomo nor patients: In several nations, governments have enacted legislation and policies intended to increase the availability of critical drugs like EPO. The purpose of these policies is to reduce the confusion and barriers faced by patients in terms of access to appropriate care and medicines.

These developments improve the availability of erythropoietin drugs, enhance treatment, coordinate patient care, and increase future research investments. As this situation changes, so will many of these changes be necessary to manage anemia in the future.

Strategic Growth Opportunities for Erythropoietin Drug Market

Strategically, there are factors in the erythropoietin drug market that can help achieve growth in several applications. These opportunities have the potential to improve current treatment options, leading to better outcomes for patients. Some of these opportunities include the following:

• Expansion of Biosimilar Offerings: The development and commercialization of biosimilars will represent a new business development opportunity for companies due to the rising demand for low-cost treatments. This expansion can widen patient accessibility and encourage growth in regions with a high prevalence of anemia.
• Development of Combination Therapies: The use of EPO in combination with other modalities to treat anemia presents an opportunity for growth. Clinical trials investigating the effects of combination therapies on patient management can be a fruitful venture for organizations.
• Research in Pediatric Applications: There is an increasing demand for efficient anemia treatment in the pediatric population. If the practice of developing appropriate EPO formulations and testing their safety and effectiveness in children continues, new markets will be created, and the health of young patients will improve.
• Focus on Patient Education Programs: Implementing patient education programs can help promote the understanding of anemia and the benefits of EPO therapy. The knowledge imparted to patients can help increase diagnosis rates and compliance with treatment by healthcare providers.
• Utilization of Digital Health Platforms: Incorporating medical practices, including telehealth and mobile health applications, can improve patient control and management. Factors such as these platforms improve accessibility to care services, especially for people living in remote areas, hence boosting the market.

These strategic growth opportunities in the erythropoietin drug market have the potential to improve patient care and expand treatment choices while stimulating innovative thinking. Focusing on such growth opportunities will allow stakeholders to promote systemic efforts against anemia for better outcomes.

Erythropoietin Drug Market Driver and Challenges

A number of drivers and challenges present in the erythropoietin drug market can affect the growth and development of this market. Dominant market factors include those that are technological, economic, and regulatory which all, affect the market therein. Given below is some explanation of various drivers and challenges present in the sector.

The factors responsible for driving the erythropoietin drug market include:

• Technological Advancements: Further developments in biotechnology are progressing into new formulations and modes of delivery of the natural erythropoietin. These improvements facilitate treatment practices and thus widen the market opportunities.
• Growing Prevalence of Anemia: The growing incidence of anemia caused by chronic diseases, the aging population, and lifestyle practices has in turn increased the demand for erythropoietin therapies. This rising prevalence drives market growth as more patients seek effective treatments.
• Biosimilar Competition: The biosimilars have entered the competitive space occupied by erythropoietin when enhancing competition and reducing costs. Such trends improve patients' access to therapies, especially in countries where cost is a key factor in therapy.
• Regulatory Support for Innovation: There appears to be shifting in attitude by regulatory bodies towards new therapeutic agents and biosimilars to make their approval processes more efficient. This kind of environment stimulates pharmaceutical corporations to fund R&D activities helping to bring about advances.
• Awareness and Education Initiatives: The rise in knowledge of anemia and its treatment is also helping healthcare providers and patients to make the correct diagnosis and start treating it quicker. Market Outlook is determined not only by marketing strategies and product innovation but also by the level of education of the patients.

Challenges in the erythropoietin drug market are:

• Limited Patient Awareness: Despite educational efforts targeting healthcare professionals, many patients are unaware of anemia or the efficacy of EPO therapies. This knowledge deficit may lead to delayed or incorrect diagnoses, resulting in suboptimal management and adverse health outcomes. There is a significant need for improved patient education to raise therapy initiation rates.
• Competition from Biosimilars: While biosimilars offer more treatment options and make therapy more affordable, there is a downside in the form of heightened competition. This competition may lead to price wars, potentially straining the sales of branded EPO products. Companies need to find innovative ways to stay competitive in this changing environment.
• Safety and Efficacy Concerns: Patient safety and efficacy concerns, particularly for certain patients, can act as barriers to treatment. Issues such as increased risk of hypertension and thrombosis from EPO therapy may affect treatment decisions. Ongoing studies and post-marketing surveillance will be required to address these concerns.

Commercially, these challenges affect the market by limiting reach, compliance, and patient outcomes. Solving these challenges through enhanced education, regulation, and ongoing technological development is crucial to improving the efficacy of EPO therapies and expanding the market.

List of Erythropoietin Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies erythropoietin drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the erythropoietin drug companies profiled in this report include-

• Johnson & Johnson
• Novartis
• Teva Pharmaceutical Industries
• Amgen
• F. Hoffmann-La Roche
• LG Chem
• Biocon
• Intas Pharmaceuticals
• Sun Pharmaceutical Industries
• Dr. Reddy's Laboratories

Erythropoietin Drug by Segment

The study includes a forecast for the global erythropoietin drug market by type, product, application, and region.

Erythropoietin Drug Market by Type [Analysis by Value from 2019 to 2031]:

• Biologic
• Biosimilar

Erythropoietin Drug Market by Product [Analysis by Value from 2019 to 2031]:

• Erythropoietin
• Darbepoetin-Alfa

Erythropoietin Drug Market by Application [Analysis by Value from 2019 to 2031]:

• Cancer
• Renal Disease
• Neurology
• Others

Erythropoietin Drug Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Erythropoietin Drug Market

Important developments have been seen in the erythropoietin (EPO) drug market across major regions due to progress in biotechnology, the rising number of anemia cases, and the quest for effective treatment. EPO, primarily used to treat anemia in chronic kidney disease and cancer, is also seeing new formulations and delivery innovations, in addition to increasing market penetration. Major countries involved in these developments include the United States, China, Germany, India, and Japan. Each country is making unique advances in EPO therapy development.

• United States: In the U.S., erythropoietin drug market growth is fueled by the entry of new formulations and biosimilars, which have been well-received by consumers. The entry of several biosimilars, facilitated by FDA approval, has created competition, reduced prices, and extended the reach of patients in need of the drug. Clinical trials are also ongoing to determine additional indications for EPO, such as managing chemotherapy-associated anemia. Furthermore, evidence-based, compliant medications are being developed to ensure that therapy remains effective for patients.
• China: China's EPO market is poised for phenomenal growth due to rising awareness of anemia and increased healthcare expenditure. The Chinese government has actively developed policies to ensure affordable and improved access to vital drugs like EPO. Domestic companies are producing biosimilars in line with the growing demand for cost-effective treatment. Additionally, emerging research is exploring new applications for EPO, such as treating anemia of chronic disease, and improving treatment regimens in the country.
• Germany: Germany remains the largest market for erythropoietin drugs in the European Union, with favorable policies supporting innovative drug development. Recent changes include the introduction of new biosimilar EPO formulations, which are expected to increase availability as prices decrease. Research efforts are focused on evaluating EPO's indications in various conditions, with clinicians now combining EPO with other therapies to treat anemia and achieve better outcomes.
• India: The increasing incidence of cancer-related anemia and chronic kidney disease is driving the erythropoietin market in India. The development of affordable biosimilars by local pharmaceutical companies is making EPO therapy more accessible. A concerted effort is underway to educate the medical community on EPO's benefits, resulting in better diagnosis and treatment rates. Government initiatives and healthcare system development are also boosting growth in the region's erythropoietin market.
• Japan: The Japanese EPO market is heavily focused on research and development activities. The addition of new EPO formulations, such as the extended-release system, has improved patient compliance and comfort. The use of EPO as an adjunct to other treatments for anemia in chronic diseases is gaining attention. Japan's healthcare system supports the development of innovative therapies and fosters partnerships aimed at investigating new clinical uses of EPO, opening new horizons for its use.

Features of the Global Erythropoietin Drug Market

Market Size Estimates: Erythropoietin drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: Erythropoietin drug market size by type, product, application, and region in terms of value ($B).

Regional Analysis: Erythropoietin drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, product, application, and regions for the erythropoietin drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the erythropoietin drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the erythropoietin drug market by type (biologic and biosimilar), product (erythropoietin and darbepoetin-alfa), application (cancer, renal disease, neurology, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Erythropoietin Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Erythropoietin Drug Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Erythropoietin Drug Market by Type
  • 3.3.1: Biologic
  • 3.3.2: Biosimilar
• 3.4: Global Erythropoietin Drug Market by Product
  • 3.4.1: Erythropoietin
  • 3.4.2: Darbepoetin-Alfa
• 3.5: Global Erythropoietin Drug Market by Application
  • 3.5.1: Cancer
  • 3.5.2: Renal Disease
  • 3.5.3: Neurology
  • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Erythropoietin Drug Market by Region
• 4.2: North American Erythropoietin Drug Market
  • 4.2.1: North American Market by Type: Biologic and Biosimilar
  • 4.2.2: North American Market by Application: Cancer, Renal Disease, Neurology, and Others
• 4.3: European Erythropoietin Drug Market
  • 4.3.1: European Market by Type: Biologic and Biosimilar
  • 4.3.2: European Market by Application: Cancer, Renal Disease, Neurology, and Others
• 4.4: APAC Erythropoietin Drug Market
  • 4.4.1: APAC Market by Type: Biologic and Biosimilar
  • 4.4.2: APAC Market by Application: Cancer, Renal Disease, Neurology, and Others
• 4.5: ROW Erythropoietin Drug Market
  • 4.5.1: ROW Market by Type: Biologic and Biosimilar
  • 4.5.2: ROW Market by Application: Cancer, Renal Disease, Neurology, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Erythropoietin Drug Market by Type
  • 6.1.2: Growth Opportunities for the Global Erythropoietin Drug Market by Product
  • 6.1.3: Growth Opportunities for the Global Erythropoietin Drug Market by Application
  • 6.1.4: Growth Opportunities for the Global Erythropoietin Drug Market by Region
• 6.2: Emerging Trends in the Global Erythropoietin Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Erythropoietin Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Erythropoietin Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Johnson & Johnson
• 7.2: Novartis
• 7.3: Teva Pharmaceutical Industries
• 7.4: Amgen
• 7.5: F. Hoffmann-La Roche
• 7.6: LG Chem
• 7.7: Biocon
• 7.8: Intas Pharmaceuticals
• 7.9: Sun Pharmaceutical Industries
• 7.10: Dr. Reddy's Laboratories